| Identification | Back Directory | [Name]
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- | [CAS]
2648257-56-9 | [Synonyms]
STC-15
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- | [Molecular Formula]
C24H25N5O2 | [MOL File]
2648257-56-9.mol | [Molecular Weight]
415.49 |
| Hazard Information | Back Directory | [Uses]
STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases[1][2][3]. | [in vivo]
STC-15 (administered for 12 days) reduces tumor volume in mice with the MC38 colorectal syngeneic model compared to control mice[3]. | Animal Model: | MC38 colorectal syngeneic model bearing mice[3] | | Dosage: | | | Administration: | 12 days of medication | | Result: | Reduced the total number of macrophages in the tumor microenvironment. |
| [References]
[1] Wesley Peter Blackaby, et al. Polyheterocyclic compounds as mettl3 inhibitors. Patent WO2021111124A1.
[2] Ofir-Rosenfeld Y, et al. STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade[J]. European Journal of Cancer, 2022, 174: S123.
[3] Ofir-Rosenfeld Y, et al. STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[C]//MOLECULAR CANCER THERAPEUTICS. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2023, 22(12). |
|
|